Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2025 17:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
March 12, 2025 10:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx anuncia la aprobación de Evkeeza® (evinacumab) por parte de la COFEPRIS para el tratamiento de la Hipercolesterolemia Familiar Homocigota (HoFH)

CIUDAD DE MÉXICO, March 12, 2025 (GLOBE NEWSWIRE) -- Ultragenyx México S. de R. L. de C. V., una empresa biofarmacéutica enfocada en el desarrollo y comercialización de terapias innovadoras...
February 24, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Participate at Investor Conferences in March

NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
February 19, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
February 18, 2025 08:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

NOVATO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the...
February 13, 2025 16:01 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

2024 Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million 2025 Financial Guidance: Total Revenue between $640 million to $670...
February 06, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
February 05, 2025 08:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

Modified intent-to-treat group demonstrated +22.7 point (p<0.0001) treatment effect in the mean Bayley-III cognitive raw score compared to natural history data (ages 24-60 months) Older children...
January 17, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
January 12, 2025 11:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to $89...

Next Page keyboard_arrow_right